# New Dimensions for Handheld Devices

Russ Maulitz, MD, Ph.D.

Drexel University College of Medicine & Institute for Healthcare Informatics

SOL Preworkshop — 24 June 2003

## • • Proposed Outline


- Settle in, introductions, surface individual objectives
- Who we are at IHI
- o Preworkshop paradigm: design choice
  - De-stress productionizing handhelds
  - Stress concepts, trends
- Survey of current utilities & markets
- o Key trends in 2003-2005

## • • Proposed Outline (cont'd)

- Key (and interwoven) trends
  - [BREAK]
  - Evidence based medicine
  - The networked handheld
  - Patient safety
  - Patient tracking
    - For practice: <u>YourOnCall</u>
    - For education: Clerkship Companion
- Group Discussion & Look at Your Apps


### • • Emphases: Who We Are

- "Next Generation"
   Content –the order of the day
- Experience of IHI
  - End Users First and Foremost
  - Developers



### • • Hence emphases on

- Usability
- o HCI
- Mobile, wireless, & mobile-wireless space
- Newer form factors
- ... all of which are in pretty early days just now for healthcare



## • • • Economics

- IAIMS Last Month: the Plaint
  - Just when we're ready to integrate everything...
  - There's a triple witching hour facing healthcare IT
    - Downturn in economy, institutions' deferred budgets
    - Doctors keeping hands in pockets
    - HIPAA
  - (But are we really ready in any case?)
- o Questions for us
  - How do we "slot in" these apps?
  - What's the killer app? ePocrates? InfoRetriever?

## • • Markets

- Who's using what
  - At hardware and software level
  - At content level
- What talks to what
- Why use anything at all

... to figure out what's ripe for plucking, where's the low-lying fruit?


## • • Hardware: what form factor?

As provider organizations implement an increasing number of mobile health care applications, more caregivers will choose personal digital assistants than tablet computers as their mobile hardware. Do you agree or disagree?

	Amount	Percent	
Responded Agree	11	60.66 %	
Responded Disagree	72	39.34 %	


#### It matters little because

- The segments all need something different
- And they barely talk to each other




#### It matters little because

- The segments all need something different
- And they barely talk to each other, they're pretty much hived off
- And the HW just fits in, in contextappropriate manner




### Current Handheld Usage




Survey: May 2003, Drexel Med – IHI R. Maulitz, MD

### • • Current Handheld Usage



### • • Current Handheld Usage



## • • Used for what?

- o Already saw: 1° use is non-medical
- Medical
  - Rudimentary look-up
    - Overwhelmingly: simple drug look-up
      - ePocrates
      - Sanford
    - Calculators
  - Or: step up from data to knowledge

### Medical content (cont'd)

- Step up: EBM
   Tools (more on this later)
  - Very few entries anything approaching robustness
  - We drilled down on this a few months ago



HANDHELDS

#### **Bedside Consults**


New handheld programs make practicing evidence-based medicine a reality.

by Eric Vogel, Jennifer Erskine and Russell Maulitz

March 2003 - Healthcare Informatics

# But we found little to be excited about

- Lots of reasons
  - Disconnected "tower of Babel"
  - Markets "immature"
  - "Tough stuff"
- All comes down to special pleading
- You have to "belly up" and start to develop



## • • Belly up to the bar

- Our experience: worked with two companies
  - Knowledge management company
  - Electronic prescribing company
- One folded, had its IP picked up on the cheap
- The other pulled out of the enterprise, and went back to basics (junior's homework on the Web)

#### Why?

- The usual (non-technical) suspects
  - Burn rate
  - Inability to close fast enough
- But some other semi-technical issues they may not have recognized
  - Inattention to end-user needs
  - E-prescribing required access to printer next door and overnight "modem farm"

# So we decided to turn elsewhere

- o Different players, different tools
- o Roll our own
- Content houses
- (Getting ahead of the story)

... first ask...

• Why will providers and hospitals slowly show they're interested, despite all, in investing in these tools?

# Real, here-and-now, pressing needs


- Ready access to knowledge tools at point of care
- Emphasis on privacy and security
- Emphasis on trapping of <u>error</u>
   ever since IOM Report, Duke
   transplant disaster, various others

#### Error in outpatient setting

\* ≈ about <sup>2</sup>/<sub>3</sub>
of all errors,
and all three
are not Rx or
knowledge,
but relate to a
communication and
continuity of
care

#### A breakdown of outpatient errors

Where do community-based generalists make errors? To answer that question, Ashok V. Daftary, FACP, presented data from the California Academy of Family Practice analyzing errors made over a year by a group of 50 family physicians. While the information doesn't specifically describe internists, Dr. Daftary said it was the best look at ambulatory practice he had seen. Here's a breakdown of the errors:



Source: "Diagnosing and Treating Medical Errors in Family Practice," California Academy of Family Physicians Monograph, 2002.

### • • The "Content Mismatch"

- Most content still provides
  - Static information on
    - Pharmacotherapy
    - Treatment guidelines, or at best
  - Basic decision support, alerts
- Most MDs opt out and call consultant who can supply missing connectivity
- Or worse (viz.: CPOE at Cedars-Sinai)
- Most content houses haven't a clue how to bridge this gap

### Why: it's a SW and appplanning glitch




...and it's completely expected and natural

# 2<sup>nd</sup> or 3<sup>rd</sup> time we've been here



### Current "New Gutenberg"

- Upside: new metaphors for interfacing with information
- Downside: "Pseudointegration"




## But need true interaction between disparate genres of applications and content

- o Execution
- Design

### • • | Execution



### • • | Execution



### • • Design



### • • Design



# New design principles for new form factors

- Use the new metaphors
- Look for new ways to integrate
- Keep in mind a few key factors
  - STANDARDS !!!
  - Exploit connectivity
  - Evidence Based Medicine (EBM)

### • • EBM Handheld Primer

- EBM and portable information resources
- Overview of Handheld Hardware, Operating Systems
- Standard Reference Software for Handhelds
  - Calculators
  - Drug References
  - Print References on the handheld
  - "Value-Added References"
  - MEDLINE Searching

## • • Overview, continued

- Portable EBM Database:
   InfoRetriever
- o The Future
  - Upcoming Products
  - New Approaches
- Questions and Answers

## • • The Problem

o "Doctors face a serious problem keeping up to date. They do not know about important advances, feel overwhelmed by new scientific information, are not good at finding new information, and do not know how to evaluate it when it is found."

--Richard Smith, BMJ 1996

## • • Why aren't MDs up to date?

- Information explosion
- Lack of training (locating, analyzing information)
- o Time constraints

Questions just go unanswered

## • • The Solution (?)

- o Evidence-Based Medicine (EBM):
  - "The conscientious, explicit, and judicious use of current best medical evidence (from systematic research) in making clinical decisions about the care of individual patients"

-Sackett et al, 1997

#### • • Practicing EBM (Traditional)

- Clinical questions from patient care
- Finding the best, most up-to-date information, usually on MEDLINE
- Critically assessing the information for validity and importance for patients
- Applying information to individual patients
- Integrating of patient preferences, clinical expertise with best evidence from research

# • • How "Useful" is this?

 "Usefulness" equation for Medical Information Sources:

(Shaughnessy AF, Slawson DC, Bennett JH, J Fam Pract. 1994)

# • • Handheld Hardware

Palm Operating System/Units

Pocket PC Operating System/Units

### • • Palm OS Units

- Vast majority of handheld computers
- o More medical software available
- Lighter and thinner, better battery life
- Generally less expensive (B&W vs. Color)
- Less internal memory, but some expandable in various formats

### • • Pocket PC OS Units

- A minority of handhelds
- Larger, bulkier units, shorter battery life
- Mostly color units More expensive
- Large internal memory (64 MB standard)
- More expandable
- Familiar Microsoft programs
- Some EBM info resources only on PPC

# • • • Handheld Tools for EBM

- Calculators
- o Drug Guides
- o Print References on the Handheld
- Value-added References
- o MEDLINE Searching

# EvaluationConsiderations

Validity
 Peer-reviewed, referenced

Well-designed studies, up to date

• Relevance Information pertinent to question

Patient population similar to

yours

formatted

Work Indexed, searchable, well-

Installation, updates, and support

• Cost / ROI Price of software, required readers

Demo availability

#### • • • EBM Calculators

• Free products: EBM Calculator, EBM


Tables, and MedRules


o For-purchase: MD EBM, Palm Stat,

and Med Calc (requires

MathPad)

 Calculations such as Bayesian Analysis, positive predictive value, negative predictive value, NNH, NNT, relative risk, relative risk reduction, sensitivity, and specificity





## • • Drug Guides

- ePocrates Rx 4.0 and ePocrates ID
- o mobileMICROMEDEX
- LexiDrugs (interfaces with 5 minute CC)
- o Physician's Drug Handbook
- o E-prescribing: Allscripts, iScribe


### • • • Scenario One

You are seeing a 23 year old white female with a history of mild asthma, for which she takes albuterol as needed. She reports the symptoms get worse when she jogs or swims. She asks if there is something "stronger" she can take to prevent symptoms during exercise.

# • • Clinical Question

• In adults with exercise-induced asthma, are other therapies such as salmeterol, leukotriene antagonists or cromolyn sodium effective in preventing or decreasing asthma symptoms?






# Journal TOC / Abstract Services


- Most are free-of-charge
- Providers include:
  - Handheldmed.com & AvantGo
  - BMJ Publishing Group (on CogniQ platform)
  - Ovid@Hand (on CogniQ platform)
  - JournalToGo
  - Redi-Reference Clinical Update Newsletter

#### Journal TOC/Abstracts

- American Family Physician
- American Journal of Epidemiology
- Annals of Internal Medicine
- BMJ British Medical Association
- Chest

- Circulation
- Gastroenterology
- o JAMA
- Journal of Clinical Oncology
- Journal of the American College of Cardiology
- The Lancet
- The New England Journal of Medicine





# TOC / Abstract Usefulness

- Validity
  - Current
  - Not enough info information
- o Relevance
  - Unlikely to apply to the clinical question
- o Work
  - Not indexed
  - No search function

#### Print References on the Handheld


- The Merck Manual of Diagnosis and Therapy
- Harrison's Companion Handbook
- The Washington Manual
- o The Ferry Guide
- o Five Minute Clinical Consult
- Clinical Medicine Consult
- and many others


### • • Scenario Two


A 68 year old patient of yours is being admitted to the hospital for unstable angina. You give orders to start IV heparin, but the nurse tells you that she is unable to get IV access despite multiple attempts.


# • • Clinical Question

o In patients with unstable angina, is low molecular weight heparin (enoxaparin) as effective as unfractionated heparin in preventing acute MI or recurrent angina?











# Print Reference Usefulness


- Validity
  - Often not current
  - Not referenced to the evidence
- Relevance
  - Good for summary information
  - Lacking some content
- Work
  - Indexed, usually searchable
  - Often require lots of scrolling


### • • • mobileMICROMEDEX

- Drug Points (drug information data)
- AltMedDex Points (alternative medicine data)
- ToxPoints (toxicology data) and
- Clinical Points (acute care data)
- Also, Mobile Drug Reax (drug interaction tool)
- Palm or Pocket PC
- Subscription or \$79 individually, demo version











#### mobileMICROMEDEX Usefulness


- Validity
  - Written, reviewed by editorial staff
  - Updated quarterly
- Relevance
  - "Acute Care Info," some major gaps
  - Not a lot of detail about Dx or Rx
- o Work
  - Easy to navigate, well-formatted
  - Topics arranged alphabetically
  - Index / search suboptimal


#### • • The Bellevue Guide

- BMJ Publishing Group
- Topically arranged, links to evidence
- Palm platform, \$29.95, demo available
- Uses iSilo (\$17.50) reader
- Mobipocket (free) reader for release soon









**epocrates** 

m500


ced modest improvements in airflow in asthmatic patients, with minimal side effects. 1.3.

- Montelukast, a leukotriene receptor antagonist, has shown modest protection against exercise induced bronchoconstriction.
- LT modifiers have not been compared to other





14Leff JR, Busse WW, Perlman D et al. Monte-lukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced broncho-constriction. N Engl J Med 1998;339:147--52. Monte-lukast reduced the exercise-induced decrease







# The Bellevue Guide Usefulness


- Validity
  - Edited by 2 MDs
  - ? Updates
- Relevance
  - Both acute and outpatient
  - Still some gaps in content
- Work
  - Hard to navigate
  - Subtopics are large


### • • Clinical Evidence


- Published by BMJ Publishing Group
- CogniQ platform for Palm
- AvantGo platform for Palm, PocketPC
- Download selected portions of Clinical Evidence
- CogniQ platform offers TOC / abstracts
- CogniQ platform also offers full-text delivery
- Handheld trial version free for now
















# Clinical Evidence Usefulness


- Validity
  - Summarized reviews of studies
  - High quality, peer-reviewed
  - Updated monthly
- Relevance
  - Med, Surg, Nursing, Alternative
  - Have to download relevant sections
  - Some major gaps but growing
- Work
  - Arranged by organ system, topic
  - No visible search function


### MEDLINE Clinical Queries

- PubMed searching project sponsored by OHPCC, NLM and the Department of Biomedical Informatics USUHS, Uses clinical filters developed by Haynes 1994
- Unbound Medicine offer MEDLINE searching thorough the CogniQ platform









## • • • | MEDLINE Usefulness

- Validity
  - Current
  - Abstract is not the article
  - No evaluation of study quality
- Relevance
  - Filtering increases it
  - Some platforms with no detail
- Work
  - Very labor intensive

### • • InfoRetriever

- Most "mature" EBM product for PDAs
- Only available for PocketPC
- Developed by Mark Ebell at MSU and colleagues
- Expensive (\$249 for one year package subscription: InfoRetriever for Pocket PC, Internet access, daily e-mail)

### • • InfoRetriever, cont'd

- Database for Pocket PC includes
  - brief synopses of relevant, valid articles in the literature (from Evidence Based Practice)
  - Abstracts of systematic reviews from the Cochrane Database of Systematic Reviews
  - Basic prescribing information for 1200 drugs


## • • InfoRetriever, cont'd


#### o Also Includes:


- Clinical prediction rule calculators (such as the Pneumonia Severity Index), other calculators
- Calculator for diagnostic tests and history and physical examination maneuvers
- summaries of selected evidence-based practice guidelines
- Griffith's 5 Minute Clinical Consult


## • • Clinical Question


o In adults with exercise-induced asthma, are other therapies such as salmeterol, leukotriene antagonists or cromolyn sodium effective in preventing or decreasing asthma symptoms?














#### InfoRetriever 4.1 7:55a InfoRetriever Search Results: 5 Minute Clinical Consult S Asthma Etiology and causation Screening and prevention Diagnosis Prognosis Therapy and management Education


Administration

File Keys 🖛 🙌 🙉











8:01a

Symptom: Asthma (Children)

Disease: unfavourable outcome

Select a test (sorted by LR+):







More info

LOE (1a-5): 1b

Pretest:

Sensitivity: Specificity:






LR+: 1.9 LR-:


0.744

Likelihood of disease if the test is...

Pos: 56.0% Neg: 33.1%







9:28a

#### Cochrane Database abstract

4

Nedocromil sodium versus sodium cromoglycate

=

for preventing exercise-induced bronchoconstriction in asthmatics Objective

The objective of this review was to compare the effects on post-exercise lung function between prophylactic doses of nedocromil sodium (NSG) and sodium cromoglycate (SCG) in persons diagnosed with exercise-induced bronchoconstriction.

Sources

Randomized controlled trials were identified from the Cochrane Airways Review Group Asthma Register which

File Keys 🎮 珪 🕾




9:29a

0.77, 60.73), or sore throat (OR = 3.46; 95% CI: 0.32, 37.48). For these pooled comparisons, no statistically significant heterogeneity was identified. Subgroup analyses based on age, dosage of medications and timing of exercise post-inhalation were consistent with the overall pooled analyses.

#### Conclusions

No significant differences were evident between the effect of NCS and SCG during the immediate post-exercise period in adults and children with EIB with regards to pulmonary function - specifically maximum percent decrease in FEV1, complete protection, clinical protection, or side effects.





9:34a

#### **Evidence-Based Practice**

Montelukast for mild and exerciseinduced asthma

Clinical question: Is montelukast (Singulair) safe and effective for the treatment of mild, exercise-induced asthma?

Study design: Randomized controlled trial (double-blinded) (LOE = 1b)

Setting: Outpatient (specialty)

Synopsis

A total of 110 non-smoking patients aged 15 to 45 years with mild, exercise-induced asthma who were only using beta-agonists were randomized to montelukast 10 mg po qhs or matching placebo. Use of



#### \iint InfoRetriever 4.1

9:36a

patients to report a 'global assessment 🔺 of asthma control'. The latter was a scale from 0 (asthma very much better) to 6 (asthma very much worse); 3 represented no change in their asthma control. After 12 weeks, patients taking montelukast reported greater improvement than those taking placebo (73.1% better, 21.2%) unchanged, 5.8% worse, compared with 44.4% better, 46.3% unchanged, and 9.3% worse, p =0.009 by the Mantel-Haenszel chisquare statistic). In addition, fewer patients taking montelukast required rescue therapy with a beta-agonist after exercise at 12 weeks (14.3% vs. 36.0%, p < 0.05). All of the less <u>important disease-oriented endpoinas</u>



9:37a

important disease-oriented endpoings were also improved during the treatment period. Adverse effects were not more common in the treatment group, and no rebound asthma was observed after the drug was discontinued.

Bottom-line

Montelukast offers an effective, if expensive, supplement to the use of beta-agonists in mild, exercise-induced asthma. (ME)

Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotrience-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147-52.

### • • InfoRetriever Usefulness

- Validity
  - High validity of sources
  - Updated regularly
- Relevance
  - Large Database
  - Good variety of info
  - "Hit or Miss"
  - Improved with 5MCC
- Work
  - Multiple search options, but search function suboptimal (no textword-like function)

### Evidence Trek: the Next Generation

- Hardware enhancements
- Software enhancements
- Breeching of specific barriers
- Applications rolling out in 2003 et seq.
- Impact of wireless connectivity

### Hardware Enhancements: Likely Results

- Four major developments 2002-2003

  - Convergence of device types ⇒ ↑ user acceptability (less juggling)
  - Wireless add-ins ⇒ ↑
    - ability to access very new data
    - at much higher speeds

### • • Software Enhancements

- Mostly application-specific, less dramatic than hardware developments
- Need to redesign the way knowledge is structured
  - "chunk it down"
  - make it more "smart-searchable" so that query is answered with more
    - sensitivity (more likely to get answer)
    - specificity (answer more pertinent)

### • • Barriers Fall

Early Barrier	2003 & beyond
Handheld a "toy"	More of KB resident
User-hostile interface	Shallow learning curve, more graphical interface
Immature market	Handheld + Health-specific apps
US lags in connectivity	Convergent devices
Old fashioned KBs (like textbooks)	Granular, searchable databases (early version e.g. InfoRetriever)

### How to Think About It



### How to Think About It



Server based Information

Bandwidth

Just-in-Time Refreshed Information

### Near-, Medium- & Long-Term

- Near-Term: spend most time on this
  - UpToDate
  - (Physicians' Information and Education Resource)
- Medium-Term
  - YourOnCall and partners
  - ? Other
- Long-Term: for the visionaries

### • • New Near-Term Resources

- UpToDate (UTD)
  - Wellesley, Mass. private enterprise, SGIM partner known well to membership
  - Since 1989, "from physicians for physicians"
  - Until recently, CD-based, now Web format
- PIER (Physicians' Information & Education Resource)
  - Philadelphia, project of ACP-ASIM
  - Not for profit but partnering with vendors
  - Web-based from outset

# • • UpToDate: Content & Format

- Medical information from over 270 journals, summarized by UTD authors
- Text, graphics, MEDLINE abstracts, drug database
- Pocket PC platform
- o Microdrive → Wireless
- Currently in beta testing, available probably summer 2002
- o Cost ????? CME credit ??????

## • • UpToDate Usefulness


- Validity
  - Peer reviewed
  - fully referenced
  - Updated every four months
- Work
  - Easy to use
- o Relevance
  - Very thorough
  - For various patient populations

## • • UpToDate Usefulness

- Concerns
  - INDEXED???
  - SEARCHABLE??


### **UpToDate Views**


- o Organization
  - Textbook-like
  - Subspecialtyoriented but also
  - Primary careoriented
  - Includes drug database




### UpToDate Search

- Intuitive Web style interface
- Start with search-box
- Allows liberal use of "back" button
- Reflects textbook on-CD heritage










#### Internet Explorer

8:14p

#### MORTALITY AND BETA AGONIST USE

 —An association between mortality in asthmatic patients and chronic treatment with betaagonists was suggested by a case-control study. using linked health insurance data bases in Saskatchewan, Canada [1]. Sub drawn from a cohort of 12,301 patients for whom asthma medications had been prescribed between 1978 and 1987. One hundred and twenty-nine case patients who had fatal or nearfatal asthmatic episodes were matched with 655 controls who had received asthma medications but had not had fatal or nearfatal. events. Near fatal episodes were defined as a PCO2 greater than 45 mmHg and/or a need for nonelective intubation, during an acute episode. Using adjusted odds ratios for statistical comparisons (with an odds ratio >2.0) being considered a significant trend), an increased risk of death or near death from







## • • | PIER Format


- Conceived in "print free" environment
- More granular than most other resources
- Just introduced April 2002 at Annual Session of ACP, expanded ACP 2003
- Just out on Web (more or less)
- Pervasively evidence-rated if users base chooses to adopt with partnering products e.g. AllScripts

## • • Pier Content

- Organization
  - Diseases
  - Screening & Prevention
  - Complementary & Alternative Medicine
  - Ethical / Legal Issues
  - Procedures
  - Drug Resource







Index \*

TW -

2:56p

#### TouchWorks

#### PIER: Essential Hypertension, Drug...▼

Initiate drug therapy according to HTN stage and risk level. [A]

- A. Supported by at least one good randomized controlled trial (RCT).
- B. Supported by non-randomized trials, cohort studies, case-control studies, or other studies that do not meet the criteria for an RCT.
- C. Supported by expert opinion only.
- <u>Consider</u> choosing therapy that may have favorable effects on comorbid conditions, and avoid therapy that may have unfavorable

#### Recommendation

Consider a diuretic, B-blocker, or an ACE inhibitor for initial treatment of uncomplicated HTN. [A]

PIER: Essential Hypertension, Drug...▼

#### Specific Recommendations

- •Consider drug therapy for the following patients:
- •Those with stage 1 HTN (SBP 140 to 159 mm Hg or DBP 90 to 99 mm Hg) in whom lifesytle modification fails.

See table **Oral Antihypertensive Drug Treatment** for specific drug







#### 2:56p

#### TouchWorks

2:56p

#### PIER: Essential Hypertension, Drug...

- ◀ 99 mm Hg)
  - •Those in risk group C (target organ damage or diabetes mellitus) with SBP > 129 mm Hg or DBP > 84 mm Hq
  - •See table <u>Oral Antihyperten-</u>
    <u>sive Drug Treatment</u> for specific information on drug classes and doses.







#### Rationale

•Many randomized clinical trials have documented the benefit of antihypertensive drug therapy in reducing target organ damage from HTN.

#### Evidence:

- •The first large prospective trial to show benefit in treating essential HTN was the VA Cooperative Study (4862069; 4914579).
- •Since the 1960s, more than 20







翢



#### PIER: Essential Hypertension, Drug...

#### reatment

je	Side Effects	Notes	≡
5	Diuretics generally: increased glucose, cholesterol, and uric acid; hypokalemia. Photosensitivity.	Blood dyscrasias, hypercalcemia, pancreatitis, and hyponatremia are rare side effects	
10	Diuretics generally: increased glucose, cholesterol, and uric	Rare blood dyscrasias hypercalcemia, pancreatitis and	

Ш

Index ◆



Name Hydrochlorothiazide

Brand Names Aquazide®; Esidrix®; Ezide®; Hydrocot®; HydroDIURIL®; Microzide™; Oretic®

#### Canadian Brand Names


Apo-Hydro; Apo®-Hydro; Diuchlor®; Diuchlor H; HydroDiuril; Neo-Codema; Neo-Codema®; Novo-Hydrazide; Urozide®

Generic Available Yes

Therapeutic class Diuretic, Thiazide.







Essential Hypertension, Non-Drug... Prevention Screening Diagonisis Hospitalization Non-drug Therapy Drug Therapy Patient Education Consultation for Management Follow-up Rationale Evidence Comments

# • • Examples in our shop

- o YourOnCall (YOC)
  - Starts with the problem at hand: outpatient on-call circumstances
  - Brings in only those data needed to manage the patient
  - Highly standards-compliant
    - HW
    - SW
    - Clinical vocabularies

# YourOnCall Upstream piece: tablet

#### Margaret O'Houlihan

Problem List || Patient List

E	nter Term: CP		
L	Type Ter	m or Abbreviation, then Clid	ck Here
Problem Statement for CP			ICD9 Billing Code for <i>CP</i>
	Natural Language	For Master Problem List	
	CP	chest pain	Add to PL

## YourOnCall Downstream piece



Web-enabled PDA

Or

Web-enabled Cellphone (Or...

Any connected device that fits in purse or belt)

Shell out to relevant content from <u>this</u> patient's problems

# • • Clerkship Companion

o Arnold Smolen, Ph.D.

# • • Key Question

- Does form follow function?
- o Does function follow form?

### Next Generation PDA+Browserphone

- In the PalmOS world
- Features
  - Accepts SD card
  - New browser
    - Handles JavaScript
    - Downloads
  - Camera
  - Brightness = iPaq x 4
  - Scrolling SMS
  - Decent battery



Handspring (merging with Palm) model 600 fall 2003

### **Examples of Utility**

- o From last week's NEJM !!!
- Think about use of
  - Push
  - Or at least <u>instant pull</u>
- Examples
  - Inpatient setting: Clinical Alerts
  - Outpatient setting: <u>YourOnCall</u> (under development in IHI)



### **Next Generation Devices**

- o In other worlds
- o Sharp Zaurus
  - Linux
  - Geek's dream
  - Usability issues
- Pocket PC world
  - "MiPad" White Paper was 3 years ago
  - Pleistocene in Internet years





# More important: next gen apps

- Clerkship Companion
- o YourOnCall (YOC)

### • • Long Term

- Go beyond "fetch for me"
- Holy grail of "think with me"
- GENERAL DISCUSSION



## • • Questions

Email

russell.maulitz@drexel.edu

On the Web

http://www.cis.drexel.edu/research/ihi